The Readout Loud
Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Is pharma scared of Kamala Harris? Are there second acts in biotech? And why don't Covid-19 trials look more diverse?